The world of biomarker research has changed dramatically over the last 20 years with targeted therapy fundamentally changing drug development practices; there are not only new biomarkers but there are also complex biomarkers such as PD-L1. Due to this, the situation has moved to a matrix of therapeutics and companion diagnostics, rather than the direct 1:1 relationship of the past.

свернуть